Veru Announces Proposed Public Offering
Veru (NASDAQ: VERU) announced on October 29, 2025 that it has commenced an underwritten public offering of shares of common stock (or pre-funded warrants) together with accompanying Series A and Series B warrants. The offering is subject to market and other conditions and may not be completed.
Use of proceeds is stated as funding development of enobosarm with a primary focus on the Phase 2b PLATEAU clinical study, plus working capital, existing vendor obligations, and potential development partner activities. Canaccord Genuity and Oppenheimer are joint book-running managers. The securities will be offered under a shelf registration statement on Form S-3 declared effective April 14, 2023, with a preliminary prospectus supplement to be filed with the SEC.
Veru (NASDAQ: VERU) ha annunciato il 29 ottobre 2025 di aver avviato un'offerta pubblica sottoscritta di azioni ordinarie (o warrant prefinanziati) insieme ai warrant di Serie A e Serie B. L'offerta è soggetta a condizioni di mercato e ad altre condizioni e potrebbe non essere completata.
Utilizzo dei proventi è indicato come finanziamento dello sviluppo dell'enobosarm con un focus primario sullo studio clinico di fase 2b PLATEAU, oltre a capitale circolante, obblighi verso fornitori esistenti e potenziali attività di partner di sviluppo. Canaccord Genuity e Oppenheimer sono gestori congiunti del book-running. Le azioni saranno offerte nell'ambito di una registrazione shelf sulla Form S-3 dichiarata efficace il 14 aprile 2023, con un supplemento di prospetto preliminare da presentare alla SEC.
Veru (NASDAQ: VERU) anunció el 29 de octubre de 2025 que ha iniciado una oferta pública suscrita de acciones ordinarias (o warrants prefinanciados) junto con warrants de Serie A y Serie B acompañando. La oferta está sujeta a condiciones de mercado y a otras condiciones y puede no completarse.
Uso de los fondos se indica como financiación del desarrollo de enobosarm con un enfoque principal en el estudio clínico de fase 2b PLATEAU, además de capital de trabajo, obligaciones hacia proveedores existentes y posibles actividades de un socio de desarrollo. Canaccord Genuity y Oppenheimer son gestores conjuntos de libros. Los valores se ofrecerán bajo una declaración de registro tipo shelf en el Formulario S-3 declarada eficaz el 14 de abril de 2023, con un suplemento de prospecto preliminar que se presentará ante la SEC.
Veru (NASDAQ: VERU)는 2025년 10월 29일에 보통주(또는 자금조달 예비 워런트)와 함께 시리즈 A 및 시리즈 B 워런트를 동반한 공개 매출 공모를 시작했다고 발표했습니다. 이번 공모는 시장 및 기타 조건에 따르며 완료되지 않을 수도 있습니다.
자금의 용도는 엔오보사름(enobosarm)의 개발 자금을 위주로 2b 단계 PLATEAU 임상 연구에 초점을 두고, 운전자본, 기존 벤더 의무 및 개발 파트너 활동 가능성과 함께 사용될 예정입니다. Canaccord Genuity와 Oppenheimer는 공동 북런칭 매니저입니다. 이 증권은 2023년 4월 14일에 효력이 선언된 Form S-3의 shelf 등록 명세서에 따라 제공되며, SEC에 제출될 예비 설문보충서가 있습니다.
Veru (NASDAQ: VERU) a annoncé le 29 octobre 2025 avoir commencé une offre publique souscrite d'actions ordinaires (ou warrants pré-financés) accompagnée de warrants de Série A et de Série B. L'offre est soumise à des conditions de marché et à d'autres conditions et pourrait ne pas être réalisée.
Utilisation des produits est indiquée comme le financement du développement de l'enobosarm avec un focus principal sur l'étude clinique de phase 2b PLATEAU, ainsi que sur le fonds de roulement, les obligations envers les fournisseurs existants et les éventuelles activités d'un partenaire de développement. Canaccord Genuity et Oppenheimer sont les gestors conjoints du book-running. Les valeurs seront offertes dans le cadre d'un shelf registration Statement sur Form S-3 déclarée efficace le 14 avril 2023, avec un supplément de prospectus préliminaire à déposer auprès de la SEC.
Veru (NASDAQ: VERU) hat am 29. Oktober 2025 bekannt gegeben, dass es eine unterbreitete öffentliche Emission von Stammaktien (oder vorfinanzierten Warrants) zusammen mit begleitenden Serie-A- und Serie-B-Warrants aufgenommen hat. Das Angebot ist von Markt- und anderen Bedingungen abhängig und möglicherweise nicht abgeschlossen.
Verwendung der Erlöse wird angegeben als Finanzierung der Entwicklung von Enobosarm mit Schwerpunkt auf der Phase-2b PLATEAU-klinischen Studie, sowie Working Capital, bestehenden Lieferantenverpflichtungen und möglichen Aktivitäten eines Entwicklungspartners. Canaccord Genuity und Oppenheimer sind gemeinsame Book-Running-Manager. Die Wertpapiere werden im Rahmen einer Shelf-Registrationserklärung auf Form S-3 angeboten, die am 14. April 2023 wirksam erklärt wurde, mit einem beigefügten vorläufigen Prospektzusatz, der bei der SEC eingereicht wird.
فيرو (NASDAQ: VERU) أعلنت في 29 أكتوبر 2025 أنها بدأت عرضاً عاماً مكتتباً لأسهم عادية (أو warrants مُموّلة مسبقاً) مع warrants من الفئة A والفئة B المرفقة. العرض خاضع لظروف السوق وغيرها من الشروط وربما لا يكتمل.
استخدام العائدات مذكور كمصدر تمويل لتطوير الإنوبوسارم مع تركيز رئيسي على الدراسة الإكلينيكية المرحلة 2b PLATEAU، إضافة إلى رأس المال العامل، والالتزامات تجاه الموردين الحاليين وأنشطة محتملة لشريك تطوير. Canaccord Genuity وOppenheimer هما المدراء المشاركون في إدارة الكتب. ستُعرض الأوراق المالية بموجب بيان تسجيل من رف Shelf على النموذج S-3 الذي صدر باعتباره فعالاً في 14 أبريل 2023، مع ملحق نشرة إرشادية أولية سيتم تقديمه إلى هيئة الأوراق المالية الأميركية SEC.
Veru (NASDAQ: VERU) 于 2025年10月29日宣布已启动一项以承销方式发行普通股（或事先资金化的认股权证）并附带 Series A 与 Series B 认股权证的公开发行。此次发行受市场及其他条件约束，可能不会完成。
募集资金用途 指定用于开发恩博索帕姆（enobosarm）的资金，其中主要聚焦于 阶段2b PLATEAU 临床研究，以及营运资金、现有供应商义务和潜在开发伙伴活动。Canaccord Genuity 与 Oppenheimer 为共同账册管理人。证券将根据自2023年4月14日生效的表格 S-3 的架 shelf 注册说明提供，并将向美国证券交易委员会（SEC）提交一份初步招股说明书补充文件。
- Net proceeds earmarked to fund enobosarm Phase 2b PLATEAU
- Engaged Canaccord Genuity and Oppenheimer as joint book-runners
- Offering registered on Form S-3 effective April 14, 2023
- Offering is subject to market and other conditions; completion not guaranteed
- Sale of common stock and warrants will likely increase outstanding securities and dilute existing shareholders
Insights
Veru has launched a dilutive equity offering to fund its Phase 2b enobosarm study; execution and size determine investor impact.
Veru proposes an underwritten public offering of common stock (or pre-funded warrants) together with Series A and Series B warrants to raise proceeds to fund development of enobosarm, prioritizing the Phase 2b
The primary dependency is the final offering size and terms, which determine dilution and runway; execution risk includes market conditions and investor appetite. Watch for the filed preliminary prospectus supplement for the offering size, strike/pricing of the accompanying warrants, and the expected use of proceeds timing; those items will clarify near-term dilution, cash runway and the ability to complete the
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock. All securities to be sold in the proposed public offering will be offered by Veru. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Veru intends to use the net proceeds from the proposed offering to fund the development of enobosarm, with a primary focus on Phase 2b PLATEAU clinical study activities. Some of the proceeds will also be used for working capital purposes, including existing vendor obligations, and for other general corporate purposes including working with potential development partners for enobosarm.
Canaccord Genuity LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.
The shares of common stock, pre-funded warrants and accompanying Series A warrants and Series B warrants, and shares of common stock issuable upon exercise of the pre-funded warrants, Series A warrants and Series B warrants, are being offered by Veru pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) on March 16, 2023 which was amended on April 11, 2023 and declared effective by the SEC on April 14, 2023. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the website of the SEC at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained when available by contacting Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, Suite 3000, Boston, Massachusetts 02109, or by telephone at (617) 371-3900, or by email at prospectus@cgf.com; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Veru Inc.
Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases.
Cautionary Statement on Forward Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to Veru’s expectations regarding the timing of the proposed public offering, the size and expected gross proceeds from the offering and the anticipated use of proceeds from the proposed offering. The words "anticipate," "believe," "could," "expect, " "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of Veru Inc. (the Company) and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statements contained in this press release because of current information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed public offering and the Company’s expectations regarding the completion, timing and size of the proposed public offering and the use of proceeds therefrom. This list is not exhaustive and other risks are detailed in the Company’s periodic reports filed with the SEC, including the Company's Form 10-K for the year ended September 30, 2024 and subsequent Quarterly Reports on Form 10-Q.
Investor and Media Contact:
Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: veruinvestor@verupharma.com
FAQ
What did Veru (VERU) announce on October 29, 2025?
How will Veru use proceeds from the VERU offering?
Who are the book-running managers for the Veru (VERU) offering?
Is the Veru (VERU) offering guaranteed to close?
Where can investors find the Veru (VERU) prospectus for the offering?
What registration covers the Veru (VERU) securities being offered?
